nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CTSG—cardiac atrium—adrenal gland cancer	0.0135	0.0368	CbGeAlD
Bortezomib—PSMD1—adrenal cortex—adrenal gland cancer	0.0132	0.0359	CbGeAlD
Bortezomib—PSMA1—gonad—adrenal gland cancer	0.013	0.0354	CbGeAlD
Bortezomib—CYP2C19—urine—adrenal gland cancer	0.0121	0.0328	CbGeAlD
Bortezomib—CTSG—adrenal gland—adrenal gland cancer	0.0118	0.0321	CbGeAlD
Bortezomib—PSMD2—adrenal cortex—adrenal gland cancer	0.0117	0.0318	CbGeAlD
Bortezomib—PSMB8—adrenal cortex—adrenal gland cancer	0.0116	0.0316	CbGeAlD
Bortezomib—PSMA1—adrenal gland—adrenal gland cancer	0.0114	0.0308	CbGeAlD
Bortezomib—PSMD1—cardiac atrium—adrenal gland cancer	0.0109	0.0297	CbGeAlD
Bortezomib—PSMD1—pituitary gland—adrenal gland cancer	0.0107	0.029	CbGeAlD
Bortezomib—PSMB5—adrenal cortex—adrenal gland cancer	0.0103	0.0279	CbGeAlD
Bortezomib—CYP1A2—urine—adrenal gland cancer	0.00986	0.0268	CbGeAlD
Bortezomib—PSMD2—gonad—adrenal gland cancer	0.00969	0.0263	CbGeAlD
Bortezomib—PSMD2—cardiac atrium—adrenal gland cancer	0.00967	0.0263	CbGeAlD
Bortezomib—PSMD1—adrenal gland—adrenal gland cancer	0.00953	0.0259	CbGeAlD
Bortezomib—PSMD2—pituitary gland—adrenal gland cancer	0.00945	0.0257	CbGeAlD
Bortezomib—PSMB8—pituitary gland—adrenal gland cancer	0.00939	0.0255	CbGeAlD
Bortezomib—CYP2C9—urine—adrenal gland cancer	0.00936	0.0254	CbGeAlD
Bortezomib—PSMB1—adrenal cortex—adrenal gland cancer	0.00897	0.0244	CbGeAlD
Bortezomib—PSMB2—adrenal cortex—adrenal gland cancer	0.00876	0.0238	CbGeAlD
Bortezomib—PSMB5—cardiac atrium—adrenal gland cancer	0.00849	0.0231	CbGeAlD
Bortezomib—PSMD2—adrenal gland—adrenal gland cancer	0.00844	0.0229	CbGeAlD
Bortezomib—PSMB8—adrenal gland—adrenal gland cancer	0.00839	0.0228	CbGeAlD
Bortezomib—PSMB5—pituitary gland—adrenal gland cancer	0.0083	0.0225	CbGeAlD
Bortezomib—SLC31A1—adrenal cortex—adrenal gland cancer	0.00758	0.0206	CbGeAlD
Bortezomib—PSMB1—gonad—adrenal gland cancer	0.00743	0.0202	CbGeAlD
Bortezomib—PSMB1—cardiac atrium—adrenal gland cancer	0.00742	0.0202	CbGeAlD
Bortezomib—PSMB5—adrenal gland—adrenal gland cancer	0.00741	0.0201	CbGeAlD
Bortezomib—PSMB2—gonad—adrenal gland cancer	0.00725	0.0197	CbGeAlD
Bortezomib—PSMB1—pituitary gland—adrenal gland cancer	0.00725	0.0197	CbGeAlD
Bortezomib—PSMB2—cardiac atrium—adrenal gland cancer	0.00724	0.0197	CbGeAlD
Bortezomib—CYP3A4—urine—adrenal gland cancer	0.00713	0.0194	CbGeAlD
Bortezomib—PSMB2—pituitary gland—adrenal gland cancer	0.00708	0.0192	CbGeAlD
Bortezomib—CYP2D6—urine—adrenal gland cancer	0.00702	0.0191	CbGeAlD
Bortezomib—PSMB1—adrenal gland—adrenal gland cancer	0.00648	0.0176	CbGeAlD
Bortezomib—PSMB2—adrenal gland—adrenal gland cancer	0.00632	0.0172	CbGeAlD
Bortezomib—SLC31A1—gonad—adrenal gland cancer	0.00628	0.0171	CbGeAlD
Bortezomib—SLC31A1—cardiac atrium—adrenal gland cancer	0.00627	0.017	CbGeAlD
Bortezomib—SLC31A1—pituitary gland—adrenal gland cancer	0.00613	0.0167	CbGeAlD
Bortezomib—SLC31A1—adrenal gland—adrenal gland cancer	0.00547	0.0149	CbGeAlD
Bortezomib—CYP2C8—pituitary gland—adrenal gland cancer	0.00225	0.00613	CbGeAlD
Bortezomib—CYP1A1—cardiac atrium—adrenal gland cancer	0.00213	0.00579	CbGeAlD
Bortezomib—PTGS1—cardiac atrium—adrenal gland cancer	0.00187	0.00509	CbGeAlD
Bortezomib—PTGS1—pituitary gland—adrenal gland cancer	0.00183	0.00497	CbGeAlD
Bortezomib—PTGS1—adrenal gland—adrenal gland cancer	0.00163	0.00444	CbGeAlD
Bortezomib—PSMA1—Signaling Pathways—IGF1R—adrenal gland cancer	0.000147	0.000232	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—EGFR—adrenal gland cancer	0.000146	0.000231	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IGF1R—adrenal gland cancer	0.000146	0.000231	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—EGFR—adrenal gland cancer	0.000145	0.00023	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IGF1R—adrenal gland cancer	0.000145	0.00023	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SDHB—adrenal gland cancer	0.000145	0.000229	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—EGFR—adrenal gland cancer	0.000145	0.000229	CbGpPWpGaD
Bortezomib—PSMA1—Disease—BRAF—adrenal gland cancer	0.000143	0.000226	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000142	0.000225	CbGpPWpGaD
Bortezomib—PSMD1—Disease—BRAF—adrenal gland cancer	0.000142	0.000225	CbGpPWpGaD
Bortezomib—PSMD2—Disease—BRAF—adrenal gland cancer	0.000142	0.000224	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PRKACA—adrenal gland cancer	0.000141	0.000223	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PRKACA—adrenal gland cancer	0.000141	0.000223	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PRKACA—adrenal gland cancer	0.000141	0.000223	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000139	0.00022	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PRKACA—adrenal gland cancer	0.000139	0.000219	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TERT—adrenal gland cancer	0.000137	0.000216	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TERT—adrenal gland cancer	0.000137	0.000216	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TERT—adrenal gland cancer	0.000137	0.000216	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—GNAS—adrenal gland cancer	0.000136	0.000216	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—GNAS—adrenal gland cancer	0.000136	0.000216	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—GNAS—adrenal gland cancer	0.000136	0.000216	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TERT—adrenal gland cancer	0.000135	0.000213	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—GNAS—adrenal gland cancer	0.000134	0.000213	CbGpPWpGaD
Bortezomib—PSMA1—Cell Cycle—TP53—adrenal gland cancer	0.000134	0.000212	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ABCB1—adrenal gland cancer	0.000134	0.000212	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ABCB1—adrenal gland cancer	0.000134	0.000212	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ABCB1—adrenal gland cancer	0.000134	0.000212	CbGpPWpGaD
Bortezomib—PSMD1—Cell Cycle—TP53—adrenal gland cancer	0.000133	0.000211	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SDHB—adrenal gland cancer	0.000133	0.000211	CbGpPWpGaD
Bortezomib—PSMD2—Cell Cycle—TP53—adrenal gland cancer	0.000133	0.00021	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SDHB—adrenal gland cancer	0.000132	0.000209	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ABCB1—adrenal gland cancer	0.000132	0.000209	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—BAD—adrenal gland cancer	0.000129	0.000204	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—BAD—adrenal gland cancer	0.000129	0.000204	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—BAD—adrenal gland cancer	0.000129	0.000204	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000128	0.000202	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—BAD—adrenal gland cancer	0.000127	0.000201	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TERT—adrenal gland cancer	0.000126	0.0002	CbGpPWpGaD
Bortezomib—CYP1A2—Biological oxidations—POMC—adrenal gland cancer	0.000126	0.0002	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TERT—adrenal gland cancer	0.000126	0.000199	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TERT—adrenal gland cancer	0.000125	0.000198	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000122	0.000192	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—POMC—adrenal gland cancer	0.000121	0.000192	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—POMC—adrenal gland cancer	0.000121	0.000191	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MED12—adrenal gland cancer	0.000121	0.000191	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—POMC—adrenal gland cancer	0.00012	0.00019	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDC42—adrenal gland cancer	0.000119	0.000189	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDC42—adrenal gland cancer	0.000119	0.000189	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDC42—adrenal gland cancer	0.000119	0.000189	CbGpPWpGaD
Bortezomib—PSMB2—Disease—BAD—adrenal gland cancer	0.000119	0.000188	CbGpPWpGaD
Bortezomib—PSMB1—Disease—BAD—adrenal gland cancer	0.000119	0.000188	CbGpPWpGaD
Bortezomib—PSMB5—Disease—BAD—adrenal gland cancer	0.000119	0.000188	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDC42—adrenal gland cancer	0.000118	0.000186	CbGpPWpGaD
Bortezomib—PSMB8—Disease—BAD—adrenal gland cancer	0.000117	0.000186	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTGS2—adrenal gland cancer	0.000115	0.000183	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF2—adrenal gland cancer	0.000115	0.000182	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF2—adrenal gland cancer	0.000115	0.000182	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF2—adrenal gland cancer	0.000115	0.000182	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTGS2—adrenal gland cancer	0.000115	0.000182	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTGS2—adrenal gland cancer	0.000114	0.000181	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—GNAS—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—GNAS—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—GNAS—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—SDHD—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—RRM1—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000114	0.00018	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF2—adrenal gland cancer	0.000113	0.000179	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SDHB—adrenal gland cancer	0.000113	0.000178	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—GNAS—adrenal gland cancer	0.000112	0.000178	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CTNNB1—adrenal gland cancer	0.000112	0.000177	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CTNNB1—adrenal gland cancer	0.000111	0.000176	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IGF1R—adrenal gland cancer	0.000111	0.000176	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IGF1R—adrenal gland cancer	0.000111	0.000176	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IGF1R—adrenal gland cancer	0.000111	0.000176	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CTNNB1—adrenal gland cancer	0.000111	0.000175	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—EGFR—adrenal gland cancer	0.000111	0.000175	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—EGFR—adrenal gland cancer	0.000111	0.000175	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—EGFR—adrenal gland cancer	0.000111	0.000175	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—BAD—adrenal gland cancer	0.00011	0.000174	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IGF1R—adrenal gland cancer	0.00011	0.000174	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—BAD—adrenal gland cancer	0.000109	0.000173	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—EGFR—adrenal gland cancer	0.000109	0.000173	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—BAD—adrenal gland cancer	0.000109	0.000172	CbGpPWpGaD
Bortezomib—PSMB5—Disease—BRAF—adrenal gland cancer	0.000108	0.000171	CbGpPWpGaD
Bortezomib—PSMB2—Disease—BRAF—adrenal gland cancer	0.000108	0.000171	CbGpPWpGaD
Bortezomib—PSMB1—Disease—BRAF—adrenal gland cancer	0.000108	0.000171	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.000108	0.000171	CbGpPWpGaD
Bortezomib—PSMB8—Disease—BRAF—adrenal gland cancer	0.000107	0.000169	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—RRM1—adrenal gland cancer	0.000104	0.000165	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—SDHD—adrenal gland cancer	0.000104	0.000165	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000104	0.000164	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CTNNB1—adrenal gland cancer	0.000103	0.000163	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CTNNB1—adrenal gland cancer	0.000103	0.000163	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CTNNB1—adrenal gland cancer	0.000102	0.000162	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—adrenal gland cancer	0.000101	0.000161	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—adrenal gland cancer	0.000101	0.000161	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—adrenal gland cancer	0.000101	0.000161	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—POMC—adrenal gland cancer	0.000101	0.00016	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—POMC—adrenal gland cancer	0.000101	0.00016	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—POMC—adrenal gland cancer	0.0001	0.000159	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—BRAF—adrenal gland cancer	0.0001	0.000158	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—adrenal gland cancer	0.0001	0.000158	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—BRAF—adrenal gland cancer	9.96e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—BRAF—adrenal gland cancer	9.91e-05	0.000157	CbGpPWpGaD
Bortezomib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	9.73e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTGS2—adrenal gland cancer	9.67e-05	0.000153	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTGS2—adrenal gland cancer	9.62e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TERT—adrenal gland cancer	9.57e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TERT—adrenal gland cancer	9.57e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TERT—adrenal gland cancer	9.57e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTGS2—adrenal gland cancer	9.57e-05	0.000151	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TERT—adrenal gland cancer	9.44e-05	0.000149	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—RRM1—adrenal gland cancer	9.33e-05	0.000148	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—SDHD—adrenal gland cancer	9.33e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—POMC—adrenal gland cancer	9.18e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—POMC—adrenal gland cancer	9.18e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—POMC—adrenal gland cancer	9.18e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—POMC—adrenal gland cancer	9.05e-05	0.000143	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	8.87e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—EGFR—adrenal gland cancer	8.86e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—EGFR—adrenal gland cancer	8.82e-05	0.00014	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PRKACA—adrenal gland cancer	8.8e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—EGFR—adrenal gland cancer	8.78e-05	0.000139	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTGS2—adrenal gland cancer	8.75e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTGS2—adrenal gland cancer	8.75e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTGS2—adrenal gland cancer	8.75e-05	0.000138	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	8.7e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTGS2—adrenal gland cancer	8.62e-05	0.000136	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	8.6e-05	0.000136	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—SDHD—adrenal gland cancer	8.58e-05	0.000136	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RRM1—adrenal gland cancer	8.58e-05	0.000136	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RRM1—adrenal gland cancer	8.5e-05	0.000135	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—SDHD—adrenal gland cancer	8.5e-05	0.000135	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MED12—adrenal gland cancer	8.5e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CTNNB1—adrenal gland cancer	8.48e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CTNNB1—adrenal gland cancer	8.48e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CTNNB1—adrenal gland cancer	8.48e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CTNNB1—adrenal gland cancer	8.36e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BAD—adrenal gland cancer	8.33e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BAD—adrenal gland cancer	8.33e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BAD—adrenal gland cancer	8.33e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BAD—adrenal gland cancer	8.21e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMA1—Disease—EGFR—adrenal gland cancer	8.18e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMD1—Disease—EGFR—adrenal gland cancer	8.14e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMD2—Disease—EGFR—adrenal gland cancer	8.1e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CTNNB1—adrenal gland cancer	7.83e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CTNNB1—adrenal gland cancer	7.83e-05	0.000124	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CTNNB1—adrenal gland cancer	7.83e-05	0.000124	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MED12—adrenal gland cancer	7.79e-05	0.000123	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CTNNB1—adrenal gland cancer	7.72e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—POMC—adrenal gland cancer	7.68e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—POMC—adrenal gland cancer	7.68e-05	0.000121	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—POMC—adrenal gland cancer	7.68e-05	0.000121	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	7.6e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—BRAF—adrenal gland cancer	7.58e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—BRAF—adrenal gland cancer	7.58e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—BRAF—adrenal gland cancer	7.58e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—POMC—adrenal gland cancer	7.57e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—BRAF—adrenal gland cancer	7.48e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTGS2—adrenal gland cancer	7.32e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTGS2—adrenal gland cancer	7.32e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTGS2—adrenal gland cancer	7.32e-05	0.000116	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—SDHD—adrenal gland cancer	7.27e-05	0.000115	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RRM1—adrenal gland cancer	7.27e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CTNNB1—adrenal gland cancer	7.23e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTGS2—adrenal gland cancer	7.22e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CTNNB1—adrenal gland cancer	7.2e-05	0.000114	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CTNNB1—adrenal gland cancer	7.16e-05	0.000113	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GNAS—adrenal gland cancer	7.13e-05	0.000113	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ABCB1—adrenal gland cancer	7e-05	0.000111	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.96e-05	0.00011	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MED12—adrenal gland cancer	6.95e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—adrenal gland cancer	6.72e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—adrenal gland cancer	6.72e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—adrenal gland cancer	6.72e-05	0.000106	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—adrenal gland cancer	6.62e-05	0.000105	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MED12—adrenal gland cancer	6.4e-05	0.000101	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MED12—adrenal gland cancer	6.34e-05	0.0001	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	6.22e-05	9.83e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—adrenal gland cancer	6.2e-05	9.81e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—adrenal gland cancer	6.2e-05	9.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—adrenal gland cancer	6.2e-05	9.81e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PRKACA—adrenal gland cancer	6.2e-05	9.81e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—adrenal gland cancer	6.11e-05	9.67e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	6.06e-05	9.59e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—adrenal gland cancer	5.73e-05	9.06e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—adrenal gland cancer	5.7e-05	9.02e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PRKACA—adrenal gland cancer	5.68e-05	8.99e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—adrenal gland cancer	5.67e-05	8.98e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	5.67e-05	8.97e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	5.61e-05	8.87e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	5.61e-05	8.87e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	5.55e-05	8.79e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—adrenal gland cancer	5.48e-05	8.67e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—adrenal gland cancer	5.48e-05	8.67e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—adrenal gland cancer	5.48e-05	8.67e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MED12—adrenal gland cancer	5.42e-05	8.57e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—adrenal gland cancer	5.4e-05	8.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PRKACA—adrenal gland cancer	5.07e-05	8.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GNAS—adrenal gland cancer	5.02e-05	7.95e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	4.96e-05	7.84e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—adrenal gland cancer	4.93e-05	7.8e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	4.84e-05	7.66e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—adrenal gland cancer	4.81e-05	7.61e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—POMC—adrenal gland cancer	4.8e-05	7.6e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—adrenal gland cancer	4.79e-05	7.57e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—adrenal gland cancer	4.76e-05	7.54e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	4.67e-05	7.38e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	4.63e-05	7.32e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GNAS—adrenal gland cancer	4.61e-05	7.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	4.52e-05	7.15e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—adrenal gland cancer	4.52e-05	7.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—adrenal gland cancer	4.34e-05	6.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—adrenal gland cancer	4.34e-05	6.87e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—adrenal gland cancer	4.34e-05	6.87e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—adrenal gland cancer	4.28e-05	6.77e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MED12—adrenal gland cancer	4.18e-05	6.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNAS—adrenal gland cancer	4.11e-05	6.5e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—adrenal gland cancer	4.03e-05	6.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PRKACA—adrenal gland cancer	3.95e-05	6.25e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	3.86e-05	6.11e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—adrenal gland cancer	3.83e-05	6.06e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNAS—adrenal gland cancer	3.78e-05	5.98e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNAS—adrenal gland cancer	3.75e-05	5.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	3.71e-05	5.87e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	3.68e-05	5.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—adrenal gland cancer	3.65e-05	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—adrenal gland cancer	3.65e-05	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—adrenal gland cancer	3.65e-05	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—adrenal gland cancer	3.59e-05	5.69e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—POMC—adrenal gland cancer	3.38e-05	5.35e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNAS—adrenal gland cancer	3.2e-05	5.07e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—adrenal gland cancer	3.14e-05	4.97e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—POMC—adrenal gland cancer	3.1e-05	4.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	3.05e-05	4.83e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—POMC—adrenal gland cancer	2.77e-05	4.38e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—adrenal gland cancer	2.7e-05	4.27e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—POMC—adrenal gland cancer	2.55e-05	4.03e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—POMC—adrenal gland cancer	2.52e-05	3.99e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—adrenal gland cancer	2.47e-05	3.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	2.47e-05	3.91e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	2.43e-05	3.84e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—adrenal gland cancer	2.21e-05	3.49e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POMC—adrenal gland cancer	2.16e-05	3.41e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	2.03e-05	3.21e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	2.01e-05	3.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—adrenal gland cancer	1.72e-05	2.72e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POMC—adrenal gland cancer	1.66e-05	2.63e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	1.33e-05	2.1e-05	CbGpPWpGaD
